Replies to post #454097 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

There is a distinction between those two.

I'll just continue to go by the reality on the ground--a 37% immediate loss in stock price that has now increased to 44%. As you previously posted, there are practicalities staring everyone in the face.

"If the FDA says an additional trial is required then I will agree that the trial [EXCELLENCE] failed."

AVXL has reported that the AD 2b/III trial was totally successful without any qualifiers. You stated that, for Rett, any future FDA action that requires an additional trial would result in your agreement that the EXCELLENCE trial was a failure. Using that same logic, would a decision by the EMA to not approve Blarcamesine for AD result in you concluding that the AD 2b/III trial was a failure? Interesting, isn't it, how failures can be turned into successes and successes into failures! I really don't think it works quite like that--these events stand on their own in my opinion.